ClinicalTrials.gg
RecruitingNCT07645391Updated Jun 12, 2026

Targeted Early Detection Program in Men at High Genetic Risk for Prostate Cancer

An observational study in Prostate Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Recruiting at 1 site in United States. Open to male participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University of Michigan Rogel Cancer Center · Observational

How we know

From the registry’s dates

  • Started Jan 2017; still recruiting 9 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
35 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center — 7 open to participants now, 12 under way, none of them phase 3. Prostatic Neoplasms · University of Michigan Rogel Cancer Center.

Started
2017
with 2 others
Observational
3 of 36
3 open now
Primary completion
2030-01
later than 9 of 11 live
Registered
35th of 36
by date

Among the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, this one is one of 3 that started in 2017, is one of 3 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 35th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

7 of the 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 35 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Prostatic Neoplasms by University of Michigan Rogel Cancer Center, or all of them as a file.
02

Study summary

This study evaluates urinary biomarkers and PSA to help determine the best approach to early detection of prostate cancer in patients with an elevated familial risk.

03

Conditions studied

  • Prostate Carcinoma

Browse trials for

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Men at high risk for prostate cancer recruited through University of Michigan Comprehensive Cancer Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • * Age 35-70 years

    • Capable of providing
    • Prognosis of > 5 years if affected by another cancer
    • Patients need one to meet at least one of the following high genetic risk categories:

      • Known PCa-related mutations: BRCA 1 and 2, Lynch syndrome, or p53
      • Carrier of mutation in a suspected PCa-related gene: e.g., ATM, PALB2, CHEK2, RAD51D, ATR, NBN, GEN1, RAD51C, MRE11A, BRIP1, FAM175A, HOXB13
      • Obligate carriers of the above mutations (e.g. their sisters/daughters have known mutations)
      • Men with any family history of above mutation
      • Family history of breast, prostate, or ovarian cancer in at least 2 individuals, or in 1 individual diagnosed before age 50

Exclusion criteria

Exclusion Criteria:

  • * Anuria

    • Prior diagnosis or treatment for PCa
    • Failure to provide
    • \< 5 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)

Groups and cohorts

  • Observational

    Patients undergo urine and blood sample collection, provide family history of cancer and have their medical records reviewed throughout the study. Patients also undergo a digital rectal examination, complete a questionnaire and receive results of the PSA blood test and urine biomarker test. Patients with an elevated PSA level above 2.0 ng/ml (age 40-49) or 2.5 ng/ml (age 50-70) or abnormal urine test will be referred for an ultrasound-guided biopsy of the prostate gland.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Predictors of any HG PCa

    Descriptive statistics, parametric and non-parametric statistical tests will be used to summarize the clinical variables. Will estimate the prevalence and incidence. Will fit two statistical models with cross-validation to evaluate the performance characteristics (Brier score, area under curve, sensitivity, specificity, positive and negative predictive values) of SelectMDx in predicting i) HG PCa and ii) any PCa.

    Time frame: At 5-years follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Jan 2030, 156 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 156 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jan 1, 2017
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07645391
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jan 1, 2017
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Jun 12, 2026

Study contacts

Cancer AnswerLine
Contact
CancerAnswerLine@med.umich.edu
1-800-865-1125
Todd M Morgan, MD
principal investigator · University of Michigan Rogel Cancer Center
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion